Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955438 | 0.78 | ALDH1A1 (0.52) | PSMD14ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL2831815 | 0.73 | ALDH1A1 (0.46) | PSMD14ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL11692293 | 0.73 | ESR1 (0.47) | ALDH1A1CYP3A4TSHRMAPK1RECQL | |
| SCHEMBL3886595 | 0.71 | ALDH1A1 (0.52) | PSMD14ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL459307 | 0.71 | ALDH1A1 (0.60) | PSMD14ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL1858216 | 0.70 | ALDH1A1 (0.58) | ALDH1A1CYP3A4TSHRMAPK1TDP1 | |
| SCHEMBL314578 | 0.70 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7930929 | 0.69 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRL3MBTL1 | |
| Bromide SCHEMBL31286101 | 0.69 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRL3MBTL1 | |
| SCHEMBL7643693 | 0.68 | CA12 (0.48) | ALDH1A1MAPK1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| EP-2948450-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | PSMD14 4385/4885ALDH1A1 289/4885CYP3A4 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.